Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3
Elizabeth Schmitz, Abigail Ridout, Audrey L Smith, Alexandria P Eiken, Sydney A Skupa, Erin M Drengler, Sarbjit Singh, Sandeep Rana, Amarnath Natarajan, Dalia El-Gamal, Jun Lu · 2024
Read Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3 by Elizabeth Schmitz, Abigail Ridout, Audrey L Smith, Alexandria P Eiken, Sydney A Skupa, Erin M Drengler, Sarbjit Singh, Sandeep Rana, Amarnath Natarajan, Dalia El-Gamal, Jun Lu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11673838.txt.
Description
Elizabeth Schmitz and co-authors present a 2024 study on a new drug for a slow blood cancer. Targeted drugs have improved care, but about a fifth of patients relapse. Immune care has also lagged, since the tumor setting damps the immune response. The drug, SpiD3, kills cancer cells by flooding them with misfolded proteins.
The team asked whether that death style alerts the immune system. Treated cells sent out classic alarm signals that draw immune cells. In lab and animal tests, the signals formed a trail for a key immune cell type. The authors say the death style could help engage immune care. They urge more work on how drug choice shapes that engagement.
Catalog record
| CREATOR | Elizabeth Schmitz, Abigail Ridout, Audrey L Smith, Alexandria P Eiken, Sydney A Skupa, Erin M Drengler, Sarbjit Singh, Sandeep Rana, Amarnath Natarajan, Dalia El-Gamal, Jun Lu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |